1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H2 2020, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.
Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 4, 5, 3, 16 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 8, 1 and 1 molecules, respectively.
Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Bone Metastasis - Overview
- Bone Metastasis - Therapeutics Development
- Bone Metastasis - Therapeutics Assessment
- Bone Metastasis - Companies Involved in Therapeutics Development
- Bone Metastasis - Drug Profiles
- Bone Metastasis - Dormant Projects
- Bone Metastasis - Discontinued Products
- Bone Metastasis - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Bone Metastasis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Bone Metastasis - Pipeline by Ablynx NV, H2 2020
- Bone Metastasis - Pipeline by Amgen Inc, H2 2020
- Bone Metastasis - Pipeline by Bayer AG, H2 2020
- Bone Metastasis - Pipeline by Better Life Pharmaceuticals Inc, H2 2020
- Bone Metastasis - Pipeline by BiologicsMD Inc, H2 2020
- Bone Metastasis - Pipeline by BioNTech SE, H2 2020
- Bone Metastasis - Pipeline by CSPC Pharmaceutical Group Ltd, H2 2020
- Bone Metastasis - Pipeline by Deciphera Pharmaceuticals Inc, H2 2020
- Bone Metastasis - Pipeline by Genor BioPharma Co Ltd, H2 2020
- Bone Metastasis - Pipeline by Hengenix Biotech Inc, H2 2020
- Bone Metastasis - Pipeline by Hualan Biological Engineering Inc, H2 2020
- Bone Metastasis - Pipeline by ITM Isotopen Technologien Munchen AG, H2 2020
- Bone Metastasis - Pipeline by JHL Biotech Inc, H2 2020
- Bone Metastasis - Pipeline by Jiangsu Rhentai Pharmaceutical Biotechnology Co Ltd, H2 2020
- Bone Metastasis - Pipeline by Jiangsu T-mab BioPharma Co Ltd, H2 2020
- Bone Metastasis - Pipeline by Livzon Pharmaceutical Group Co Ltd, H2 2020
- Bone Metastasis - Pipeline by Lupin Ltd, H2 2020
- Bone Metastasis - Pipeline by Luye Pharma Group Ltd, H2 2020
- Bone Metastasis - Pipeline by MetCure Therapeutics LLC, H2 2020
- Bone Metastasis - Pipeline by NeuClone Pty Ltd, H2 2020
- Bone Metastasis - Pipeline by Orion Biotechnology Canada Ltd, H2 2020
- Bone Metastasis - Pipeline by Qilu Pharmaceutical Co Ltd, H2 2020
- Bone Metastasis - Pipeline by QSAM Therapeutics Inc, H2 2020
- Bone Metastasis - Pipeline by R Pharm, H2 2020
- Bone Metastasis - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2020
- Bone Metastasis - Pipeline by Serene LLC, H2 2020
- Bone Metastasis - Pipeline by Sonnet BioTherapeutics Holdings Inc, H2 2020
- Bone Metastasis - Pipeline by Terpenoid Therapeutics Inc, H2 2020
- Bone Metastasis - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2020
- Bone Metastasis - Dormant Projects, H2 2020
- Bone Metastasis - Dormant Projects, H2 2020 (Contd..1), H2 2020
- Bone Metastasis - Dormant Projects, H2 2020 (Contd..2), H2 2020
- Bone Metastasis - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Bone Metastasis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ablynx NV
- Amgen Inc
- Bayer AG
- Better Life Pharmaceuticals Inc
- BiologicsMD Inc
- BioNTech SE
- CSPC Pharmaceutical Group Ltd
- Deciphera Pharmaceuticals Inc
- Genor BioPharma Co Ltd
- Hengenix Biotech Inc
- Hualan Biological Engineering Inc
- ITM Isotopen Technologien Munchen AG
- JHL Biotech Inc
- Jiangsu Rhentai Pharmaceutical Biotechnology Co Ltd
- Jiangsu T-mab BioPharma Co Ltd
- Livzon Pharmaceutical Group Co Ltd
- Lupin Ltd
- Luye Pharma Group Ltd
- MetCure Therapeutics LLC
- NeuClone Pty Ltd
- Orion Biotechnology Canada Ltd
- Qilu Pharmaceutical Co Ltd
- QSAM Therapeutics Inc
- R Pharm
- Reliance Life Sciences Pvt Ltd
- Serene LLC
- Sonnet BioTherapeutics Holdings Inc
- Terpenoid Therapeutics Inc
- Zhejiang Hisun Pharmaceutical Co Ltd
